Stockscreener 앱 받기
3.17
2.59%
0.08
시간 외 거래:
3.20
0.03
+0.95%
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Prime Medicine: Soon In The Clinic (NASDAQ:PRME) - Seeking Alpha
Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside - TradingView
Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright - MarketBeat
Prime Medicine: An Initial Prognosis (NASDAQ:PRME) - Seeking Alpha
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Prime Medicine (NASDAQ:PRME) Trading Up 7.3%Still a Buy? - MarketBeat
Prime Medicine's (PRME) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Weekly Recap: Q2 loss/runway into 2027 and PM647 arbitration win, IND Q3 - TradingView
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Prime Medicine (NASDAQ:PRME) Announces Earnings Results, Meets Estimates - MarketBeat
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Prime Medicine, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Prime Medicine Q2 net loss narrows on lower expenses - TradingView
Prime Medicine, Inc. 2026: Revenue $11.04M, EPS ($0.24) — 10-Q Summary - TradingView
PRME: Regulatory advances and cost reductions position pipeline for key clinical milestones in 2027 - TradingView
FDA milestones and Beam ruling frame outlook for Prime Medicine (NASDAQ: PRME) - stocktitan.net
Prime Medicine reports Q2 2026 net loss $42.1M, cash $108.8M; IND/CTA clearances for PM577a - TradingView
BRIEF-Prime Medicine, Inc. Q2 EPS USD -0.24 - TradingView
Prime Medicine (PRME) Earnings Date and Reports 2026 - MarketBeat
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PRME Q2'26 Earnings: revenue estimate is 2.25M USD - TradingView
ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Inc (PRME) Cash Flow - TradingKey
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prime Medicine Inc (PRME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prime Medicine Market Sentiment - Benzinga España
Prime Medicine Inc (PRME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PRME|Prime Medicine Inc|Price:3.015|Chg%:+0.065 - TradingKey
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Prime Medicine, Inc. (PRME) and Community Health (CYH) - The Globe and Mail
Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Prime Medicine Buy Rating Reiterated as Pipeline Advances; $6 Price Target Maintained - TipRanks
PRME|Prime Medicine Inc|Price:3.040|Chg%:+0.030 - TradingKey
Prime Medicine receives FDA clearance for Wilson disease therapy - Investing.com
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease - TradingView
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore
Prime Medicine receives FDA clearance for Wilson disease therapy By Investing.com - Investing.com Canada
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease - The Manila Times
Prime Medicine expects first-in-human Wilson trial in second half of 2026 - Stock Titan
Tracking Cathie Wood: Backing Prime Medicine and SpaceX, Sells Off AtaiBeckley, Shopify - Moomoo
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
Svetlana Ni Makhni Net Worth (2026) - GuruFocus
Prime Medicine secures favorable arbitration ruling in Beam Therapeutics case - MSN
Tracking Cathie Wood: Loading Up on X-Energy and Prime Medicine, Slashing AtaiBeckley - Moomoo
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Has $10.23 Million Stock Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Prime Medicine (NASDAQ:PRME) Shares Down 6.5%Should You Sell? - MarketBeat
Prime Medicine Stock Dips As Traders Weigh Heavy Losses - timothysykes.com
Enterprise value to EBITDA forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
PRME Q1 2026 Earnings: Wider-than-Expected Loss Drags Shares LowerProfit Margin Analysis - po-news-eg.net
PRME Stock Slides As Traders Weigh Heavy Losses And Cash Runway - StocksToTrade
Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
H.C. Wainwright reiterates Prime Medicine stock rating at buy By Investing.com - Investing.com Canada
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME) - The Globe and Mail
Prime Medicine wins arbitration to advance gene editing program, shares jump over 15%. - Pluang
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
1.80%
1.77%
자본화:
|
볼륨(24시간):